Switching EU Authorised Representative: A Regulatory Guide to MDR Article 12

A change in regulatory representation serves as a comprehensive audit of a manufacturer’s compliance health rather than a simple administrative update. For non-EU manufacturers, the process of switching EU authorised representative often triggers concerns regarding labelling continuity and the integrity of technical documentation. It’s a high-stakes transition where any oversight in the tripartite agreement required by MDR Article 12 can lead to immediate market access disruptions.

We understand that maintaining stability during such a transition is paramount to your global operations. This guide provides a meticulous roadmap to mastering the legal and operational requirements of MDR and IVDR, ensuring your transition remains seamless and fully compliant. We will examine the mandatory EUDAMED registration updates that took effect on May 28, 2026, the structured transfer of technical files, and the strategic timing needed to avoid costly sales interruptions during the handover process.

Can You Change Your EU Authorised Representative? (MDR Article 12)

Manufacturers frequently inquire whether they’re legally permitted to transition their regulatory representation. The answer is found in Article 12 of Regulation (EU) 2017/745 (MDR) and Article 11 of Regulation (EU) 2017/746 (IVDR). These regulations establish a clear, structured framework for switching EU authorised representative without compromising market access or compliance status. Far from being a permanent arrangement, the choice of a representative is a strategic business decision that should be reviewed as your product portfolio or the regulatory environment evolves.

A common misconception is that a single entity must represent a manufacturer’s entire catalog. However, the regulations permit the appointment of different representatives for distinct generic device groups. This flexibility allows businesses to align their regulatory partners with the specific technical complexities of their product lines. It ensures that high-risk devices receive the specialized oversight they require while simpler devices might be managed separately. To understand the foundational role of this entity, one might ask: What is an EU Authorised Representative? Essentially, they act as the legal bridge between a non-EU manufacturer and the European competent authorities, sharing liability for compliance failures.

The transition is governed by a tripartite agreement. This formal document involves the manufacturer, the outgoing representative, and the incoming representative. It serves as the legal instrument that defines the precise moment of handover, the transfer of technical documentation, and the ongoing responsibilities for post-market surveillance. Without this coordinated approach, manufacturers risk gaps in their regulatory coverage that could lead to the suspension of sales.

Understanding Article 12 of the MDR

Article 12 formalizes the arrangements for a change of representative. It mandates that a written agreement must be accepted by both the manufacturer and the successor. This regulation protects the manufacturer by ensuring that the outgoing representative remains responsible for devices already placed on the market while the new representative assumes prospective liability. It ensures that the technical file, which remains the property of the manufacturer, is handled with strict confidentiality during the transfer. The agreement must specifically address how complaints and suspected incident reports are managed during the transition period to maintain patient safety.

Identifying When a Switch is Necessary

Manufacturers often initiate a switch when their current representative lacks the technical depth required by the evolving regulatory landscape. With four modules of EUDAMED becoming mandatory on May 28, 2026, including actor and device registration, any delay in data entry can lead to immediate sales disruptions. Signs of underperformance, such as poor communication or a lack of familiarity with ISO 13485 standards, are clear indicators that a change is required. Strategic consolidation is another driver; many firms move toward partners that offer combined auditing and representative services to streamline their global compliance footprint and reduce administrative redundancy.

The Legal Requirements of a Representative Transfer Agreement

Formalizing the transition between regulatory partners is a process dictated by strict legal standards. The tripartite agreement is the cornerstone of this transition, serving as a binding contract between the manufacturer, the outgoing representative, and the successor. According to MDR Article 12, this document must clearly define the date of termination for the outgoing representative and the date of commencement for the successor. There can’t be a gap in coverage; however, there also shouldn’t be an overlap where two entities claim the same mandate for the same device group. This precision prevents regulatory ambiguity and ensures that competent authorities always have a single, responsible point of contact within the Union.

Manufacturers should treat the transfer as a technical audit of their own documentation. While switching EU authorised representative, the manufacturer must ensure that the technical file, including all registration data and EUDAMED records, remains their exclusive property. The agreement must explicitly state that the outgoing representative has no right to withhold documentation or intellectual property as leverage in commercial disputes. This clarity is essential for maintaining the continuity of your market presence and protecting your commercial interests during the handover.

Post-Mandate Obligations and Liability

The outgoing representative’s role doesn’t end abruptly on the termination date. They’re legally required to forward any complaints or reports of suspected incidents related to devices they previously represented to the manufacturer for a defined period. This ensures that post-market surveillance remains uninterrupted. Legal protections are built into the MDR to prevent an outgoing representative from obstructing the transition by refusing to transfer necessary data. If you’re currently evaluating your regulatory needs, our team provides expert EU authorised representative services to facilitate these complex handovers with professional precision.

Confidentiality and Technical Documentation

Maintaining the integrity of ISO 13485 aligned technical files is a critical priority during the switch. The tripartite agreement must include robust confidentiality clauses to protect proprietary design and manufacturing data during the transfer. The Person Responsible for Regulatory Compliance (PRRC) plays a pivotal role here, overseeing the verification of the technical documentation as it moves from the old mandate to the new one. This oversight ensures that the successor is fully equipped to fulfill their verification duties under Article 11 without compromising the manufacturer’s trade secrets or intellectual property rights.

Managing Labelling and Inventory During the Transition

The logistical execution of a representative transition is often the most complex phase for medical device manufacturers. While the legal mandate is established through the tripartite agreement, the physical manifestation of that change appears on every label, instruction for use (IFU), and promotional asset. A critical component of switching EU authorised representative is determining the exact “cut-off” date. This date identifies when the outgoing representative’s information must be replaced by the successor’s details on all newly manufactured products. Manufacturers must notify their Notified Body of this change, as it constitutes a significant modification to the quality management system and product labelling.

Inventory management requires a disciplined approach to distinguish between devices already “placed on the market” and those still in the production or importation pipeline. Within the EU regulatory framework for medical devices, products that have already been legally placed on the Union market before the mandate’s termination date can typically be sold through the distribution chain without relabelling. However, any stock held in warehouses outside the EU or products manufactured after the commencement date must reflect the new representative’s details. Failure to coordinate this transition can lead to the quarantine of shipments at EU borders or the forced withdrawal of non-compliant stock.

Labelling Updates and Sell-Through Periods

Manufacturers must decide between implementing new production runs or utilizing over-labelling for existing inventory. Over-labelling is a permissible solution provided it’s performed under controlled conditions within an ISO 13485 certified quality system to ensure label integrity. Digital assets, including e-IFUs and corporate websites, should be updated simultaneously to maintain consistency. Because the typical timeframe to complete a change of representative is 2 to 6 weeks, manufacturers should prepare these artwork revisions well in advance to minimize the period where dual-inventory management is required.

EUDAMED and Regulatory Registration Updates

The mandatory implementation of EUDAMED modules on May 28, 2026, has heightened the technical requirements for representative transfers. Manufacturers are responsible for updating their Single Registration Number (SRN) details within the Actor Registration module to link their profile to the new representative. While the switch doesn’t necessitate a change to the Unique Device Identification (UDI) data, the registration of the new mandate in EUDAMED is a prerequisite for legal market access. Legacy devices already on the market must also be accounted for in these digital updates by the November 27, 2026, registration deadline to ensure continued compliance across the entire product lifecycle.

A 5-Step Checklist for Switching EU Authorised Representatives

Manufacturers must approach the transition with a structured mindset to mitigate operational risks. While previous sections outlined the legal and logistical foundations, this checklist provides a chronological sequence of actions. Each step is designed to ensure that switching EU authorised representative remains a controlled process that reinforces your compliance posture rather than creating vulnerabilities.

1. Conduct a technical audit of your current representative’s performance. Assess how they’ve managed your technical documentation and EUDAMED registration. Identify any outstanding non-conformities that must be resolved before the handover.
2. Vet the successor for technical competence and ISO 13485 familiarity. The new representative must possess the technical depth to verify your compliance claims. A partner with certification expertise is often preferred to ensure a high level of scrutiny.
3. Draft and execute the Tripartite Transfer Agreement. This formal document, as required by Article 12, must be signed by all three parties to establish a clear legal timeline for the transition.
4. Execute the labelling transition and EUDAMED update plan. Use the cut-off dates established in your inventory strategy to roll out updated packaging and digital registrations simultaneously.
5. Formally notify your Notified Body and key distributors. Transparent communication prevents logistical bottlenecks. It ensures that all supply chain actors are informed of the new legal point of contact within the Union.

Selecting a Technically Competent Successor

The choice of a successor should be based on their ability to act as a bridge between complex regulations and your business objectives. Manufacturers benefit from selecting a representative with a robust auditing background, such as International Associates Limited. Our expertise allows us to evaluate technical files from an auditor’s perspective, providing a proactive layer of compliance verification. If your operations involve complex supply chains, assess the successor’s proficiency in handling social accountability audits and other international standards. This holistic expertise ensures they can support your global growth while maintaining strict regulatory adherence. Secure your market presence by choosing to appoint a new EU authorised representative with our technical team today.

Notifying Stakeholders and Authorities

Regulatory transparency is a foundational requirement of the MDR. Manufacturers must draft a formal notification letter for their Notified Body that details the change in mandate. This letter should reference the tripartite agreement and confirm that the technical file transfer is complete. Simultaneously, you must communicate the change to EU importers and distributors. These entities rely on accurate representative data for their own compliance records. Finally, ensure your internal Quality Management System (QMS) is updated. All procedures related to regulatory representation and post-market surveillance must reflect the new mandate to remain compliant during future audits.

Why International Associates Limited is the Global Choice for EU Representation

Selecting a regulatory partner requires a balance between institutional reliability and localized operational capacity. International Associates Limited provides this stability through our central administrative headquarters in Glasgow, which is supported by a robust network of international offices across the European Union. This global-local duality ensures that manufacturers receive consistent, high-level expertise regardless of their geographic origin. Manufacturers often find that switching EU authorised representative to a partner with a physical presence in multiple jurisdictions provides a more secure bridge between complex global regulations and the European market.

Our approach differs from traditional legal representatives because we integrate deep auditing expertise with our representative functions. We don’t merely act as a legal signatory; we function as a technical guardian of your compliance standards. This methodical perspective is rooted in our experience as a certification body, allowing us to conduct thorough verifications of technical documentation before any mandate is signed. This proactive scrutiny reduces the risk of non-compliance during competent authority inspections and provides manufacturers with the quiet confidence needed to scale their international operations without unnecessary friction.

Dual EU and UK Representation

The post-Brexit regulatory landscape has introduced significant administrative hurdles for manufacturers targeting both the Union and the United Kingdom. We simplify these complexities by offering seamless dual representation, acting as both your EU Authorised Representative and your UK Responsible Person (UKRP). This integrated service model allows firms to manage MDR and UKCA requirements through a single, specialized partner. By utilizing our unified IT infrastructure, manufacturers can reduce their administrative burden and ensure that their regulatory data remains synchronized across both markets. This efficiency is vital for maintaining market access without the logistical burden of managing multiple, disconnected representatives.

A Technical Partner, Not Just a Legal Signatory

Our team’s proficiency is founded on a deep immersion in international standards and legal frameworks. Because our background is rooted in Lead Auditor Training, we understand the technical nuances of your files better than a standard legal firm. We don’t wait for issues to arise; we proactively monitor MDCG guidance and evolving EUDAMED requirements to keep your business ahead of regulatory shifts. This commitment to technical excellence ensures quick turnaround times for mandates and certificates. When switching EU authorised representative to International Associates Limited, you aren’t just changing an address on a label; you’re securing a meticulous, ethical partner dedicated to your long-term regulatory stability and global growth.

Securing Your Future Regulatory Stability

Adherence to MDR Article 12 ensures that the transition between regulatory mandates remains a controlled and transparent process. By formalizing the tripartite agreement and executing a precise labelling strategy, manufacturers protect their market access while maintaining the integrity of their technical documentation. Manufacturers should view the process of switching EU authorised representative as a strategic realignment that enhances their compliance health rather than a mere administrative obligation.

International Associates Limited has operated as an independent auditing body since 2005, offering a global network that spans Europe, Asia, and the Middle East. Our specialized focus on ISO 13485 and MDR compliance allows us to act as a sophisticated bridge between complex regulations and your international business objectives. We provide the stability and technical expertise required to navigate high-stakes certification landscapes with confidence. We invite you to request a technical consultation for your EU and UK representation needs to finalize your transition with institutional reliability. Maintaining your global standards remains our primary objective.

Frequently Asked Questions

Is it mandatory to have a tripartite agreement when switching EU AR?

Yes, a tripartite agreement is a mandatory legal requirement under Article 12 of the MDR. This formal document must be signed by the manufacturer, the outgoing representative, and the incoming representative to define the exact moment responsibilities are transferred. It serves as the legal mechanism to ensure that technical documentation and complaint handling procedures are handed over without a gap in regulatory coverage.

How long does it take to switch EU Authorised Representatives?

The process of switching EU authorised representative generally takes between 2 and 6 weeks to finalize. This timeframe allows for the negotiation of the tripartite agreement, the technical review of documentation, and the necessary updates within the EUDAMED database. Manufacturers should account for additional time if significant labelling revisions or production adjustments are required to reflect the new representative’s details.

Can I have two different EU Authorised Representatives at the same time?

You can’t have two different representatives for the same medical device. While Article 12 permits a manufacturer to appoint different representatives for distinct generic device groups, a single device model must have only one authorised representative within the Union. This ensures that competent authorities have a clear, singular point of contact for any specific product placed on the market.

What happens to the devices already on the market when I switch?

Devices that were legally placed on the market before the mandate termination date don’t require immediate relabelling. The outgoing representative remains responsible for these specific units regarding post-market surveillance inquiries and complaint forwarding for a period defined in the tripartite agreement. New production runs or imports occurring after the commencement date must reflect the successor’s information to maintain compliance.

Do I need to notify my Notified Body before I switch representatives?

Yes, notifying your Notified Body is a prerequisite for a compliant transition. Because the authorised representative is a core component of your regulatory infrastructure, any change constitutes a significant modification to your quality management system. The Notified Body must verify the new mandate and update their records to ensure your CE certificate remains valid under the new representation.

Does switching my EU AR affect my UKCA or UKRP status?

No, changing your EU representative doesn’t automatically affect your UKCA or UKRP status. These are governed by separate legal frameworks in the European Union and the United Kingdom. However, many manufacturers find that consolidating these roles with a single partner simplifies their compliance management and reduces the administrative burden of maintaining separate IT and documentation infrastructures for both regions.

What is the role of the PRRC during the representative transfer?

The PRRC is responsible for overseeing the integrity of the technical documentation during the transfer process. They ensure that all required records, including clinical evaluations and risk management files, are accurately transferred to the successor. This oversight is vital for the new representative to fulfill their legal obligation to verify that the manufacturer has complied with all MDR or IVDR requirements.

What are the common pitfalls to avoid when changing your mandate?

Common pitfalls include failing to set precise termination and commencement dates, which can lead to compliance gaps. The process of switching EU authorised representative also requires manufacturers to update EUDAMED actor registration promptly and coordinate labelling changes with production cycles. Avoiding these errors requires a methodical approach to prevent logistical delays at EU borders or market suspensions.